Pantethine, Cholesterol, and Calming Psoriasis Flares

Understanding how a vitamin B5 derivative modulates immune activity provides a low-cost biochemical lever for managing chronic autoimmune skin inflammation.

By Sabin · Wellness & AI3 min read
AI News
Pantethine, Cholesterol, and Calming Psoriasis Flares

Autoimmune skin disorders are routinely treated with systemic immunosuppressants or targeted biologics that carry hefty price tags and non-trivial side-effect profiles. New preclinical work paired with an early human pilot points to an unheralded metabolic intervention: pantethine, a dimeric form of pantetheine and precursor to coenzyme A.

In murine models, pantethine administration prevented the characteristic epidermal thickening of psoriasis by curbing hyperactive Th17 and dendritic cells. A preliminary clinical evaluation of human subjects mirrored this response, linking the improvement to shifts in lipid processing. The compound altered intracellular cholesterol trafficking inside circulating monocytes, muting the production of inflammatory cytokines like IL-17 and IL-23 without shutting down baseline immune defence.

Standard clinical habits treat metabolic health and autoimmune dermatology as distant neighbours. This mechanism demonstrates that intracellular lipid handling directly dictates the volume knob on cutaneous inflammation.

If you manage psoriasis, examine your lipid panels alongside inflammatory markers like hs-CRP with your physician before modifying your supplementation. High-dose coenzyme A precursors alter systemic pathways, making baseline blood data essential prior to self-directed trials.

One headline rarely tells the story. See how today’s news fits the bigger shifts on AI Trends, or learn to read your own data on How it works.

Keep reading

Based on what you've been reading — always learning.

See all →